Skip To Main Content
Bartolomé P. Gálvez on Muck Rack

Bartolomé P. Gálvez

As seen in: Science Magazine
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Bartolomé P.

Contact Bartolomé P., search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Mavoglurant reduces cocaine use in patients with cocaine use disorder in a phase 2 clinical trial

|
By Baltazar Gomez-Mancilla, Kenneth M Dürsteler, Marc Vogel, Marcus Herdener, Marta Torrens, Antoni Gual, Ricardo Corral, Bartolomé P. Gálvez, Enrique I. Kuper, Daniel L. Mosca, Swati Dumitras, Nicole Pezous, Maria Berkheimer, Ela Walker, Fabrizio Gaspar
| Science Magazine Verified
Editor’s summary Cocaine use disorder is associated with dysregulated glutamate neurotransmission. Preclinical studies have indicated that modulation of glutamate signaling by antagonizing metabotropic glutamate receptor 5 (mGluR5) can attenuate cocaine use in animal models. Gomez-Mancilla et al. conducted a randomized, placebo-controlled phase 2 clinical trial of mavoglurant, a selective noncompetitive antagonist of mGluR5, in 68 patients with chronic cocaine use disorder who also used alcohol.
Open in Who Shared Issue with article?
See all 1 articles